Bactobio uses synthetic biology, next-generation sequencing, and machine learning to culture microbes.
Bactobio has raised €7.0M across 1 funding round from 3 investors, most recently a round in Dec 2022. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-12-05 | Other | €7.0M |
| Bridford Group,Hugh Grant,Peder Holk Nielsen |
| View deal → |
